Effect of somatostatin analog on postprandial satiation in obesity.
OBJECTIVE
Altered satiation may impact postprandial symptoms and potentially change food intake in obesity. Our aim was to compare effects of octreotide and placebo on postprandial symptoms, satiation, and gastric volumes in obesity.


METHODS
In a randomized, parallel-group, double-blind, placebo-controlled study, 26 obese but otherwise healthy participants received 100 mug of octreotide or placebo subcutaneously 30 minutes before each study. Studies were performed on 2 separate days and included validated non-invasive techniques: (99m)Tc-single photon emission computed tomography imaging to measure fasting stomach volume and gastric volume changes after 90 mL of water and 240 mL of Ensure and a standardized nutrient drink test to measure the maximum tolerated volume and postprandial symptoms.


RESULTS
Relative to placebo, octreotide increased gastric volume after 90 mL of water; however, fasting and gastric volume change post-Ensure and maximum tolerated volume of Ensure were not different. Octreotide decreased sensations of fullness (p = 0.035) and bloating (p = 0.05) and tended to reduce aggregate symptoms (p = 0.07) after the fully satiating meal.


CONCLUSIONS
In obese individuals, somatostatin analog significantly reduced postprandial sensations after a satiating meal without altering maximum tolerated meal volume or postnutrient gastric volume, suggesting an effect on upper gut sensation. The role of somatostatin as a permissive factor in the development of obesity by reducing postprandial sensations deserves further study.
Cremonini
Filippo
F
Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
Camilleri
Michael
M
Gonenne
Jonathan
J
Stephens
Debra
D
Oenning
LaVonne
L
Baxter
Kari
K
Foxx-Orenstein
Amy
A
Burton
Duane
D
D000328:Adult; D004311:Double-Blind Method; D004326:Drinking; D005260:Female; D006801:Humans; D008297:Male; D009765:Obesity / Q000503:physiopathology*; D015282:Octreotide / Q000494:pharmacology*; D009929:Organ Size / Q000187:drug effects; D019518:Postprandial Period / Q000187:drug effects*; D012527:Satiation / Q000187:drug effects*; D013270:Stomach / Q000187:drug effects
D015282:Octreotide